: Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy by Wadsley et al. Thyroid 2023;33(9):1119-1123; doi: 10.1089/thy.2022.0707.
出版信息
Thyroid. 2023 Nov;33(11):1385. doi: 10.1089/thy.2022.0707.correx. Epub 2023 Oct 19.
Abstract
摘要
相似文献
1
: Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy by Wadsley et al. Thyroid 2023;33(9):1119-1123; doi: 10.1089/thy.2022.0707.瓦兹利等人进行的SEL-I-METRY II期试验结果：晚期碘难治性分化型甲状腺癌对放射性碘治疗再致敏的研究。《甲状腺》2023年；33(9)：1119 - 1123；doi: 10.1089/thy.2022.0707
Thyroid. 2023 Nov;33(11):1385. doi: 10.1089/thy.2022.0707.correx. Epub 2023 Oct 19.
2
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.研究 Selumetinib 使晚期碘难治性分化型甲状腺癌对放射性碘治疗重新敏感的潜在临床获益（SEL-I-METRY）：一项多中心英国单臂 II 期试验的方案。
BMC Cancer. 2019 Jun 14;19(1):582. doi: 10.1186/s12885-019-5541-4.
3
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.SEL-I-METRY II期试验关于晚期碘难治性分化型甲状腺癌对放射性碘治疗再致敏的结果。
Thyroid. 2023 Sep;33(9):1119-1123. doi: 10.1089/thy.2022.0707. Epub 2023 Sep 1.
4
Advances in the molecular mechanism and targeted therapy of radioactive-iodine refractory differentiated thyroid cancer.放射性碘难治性分化型甲状腺癌的分子机制与靶向治疗进展。
Med Oncol. 2023 Jul 31;40(9):258. doi: 10.1007/s12032-023-02098-3.
5
6
The Diagnostic Value of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Differentiated Thyroid Cancer Patients with Elevated Thyroglobulin/Thyroglobulin Antibody Levels and Negative Iodine Scintigraphy: A Systematic Review and Meta-Analysis by Bang et al. Thyroid 2023;33(10):1224-1236; doi: 10.1089/thy.2023.0264.F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在甲状腺球蛋白/甲状腺球蛋白抗体水平升高且碘闪烁扫描阴性的分化型甲状腺癌患者中的诊断价值：Bang等人的系统评价和荟萃分析。《甲状腺》2023年；33(10):1224 - 1236；doi: 10.1089/thy.2023.0264
Thyroid. 2024 Jan;34(1):139. doi: 10.1089/thy.2023.0264.correx. Epub 2024 Jan 2.
7
Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.高级放射性碘难治性分化型甲状腺癌：钠碘转运体及其他新兴治疗靶点。
Lancet Diabetes Endocrinol. 2014 Oct;2(10):830-42. doi: 10.1016/S2213-8587(14)70051-8. Epub 2014 Jun 2.
8
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance.放射性碘难治性分化型甲状腺癌：碘抵抗的分子机制与治疗策略。
Drug Resist Updat. 2024 Jan;72:101013. doi: 10.1016/j.drup.2023.101013. Epub 2023 Oct 22.
9
Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.晚期、转移性及放射性碘难治性分化型甲状腺癌的治疗进展
Front Endocrinol (Lausanne). 2017 Nov 20;8:312. doi: 10.3389/fendo.2017.00312. eCollection 2017.
10
Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.肽受体放射性核素治疗晚期碘难治性分化型甲状腺癌和转移性甲状腺髓样癌的疗效和安全性：系统评价。
BMC Cancer. 2021 May 20;21(1):579. doi: 10.1186/s12885-021-08257-x.
Zotero 插件